FogPharma, based in Cambridge, Mass., was founded in 2016 by several scientists including Gregory Verdine, the company’s chairman and CEO, Weiging Zhou, David Lane, and Gerard Hilinski. The company, which was valued at $406 million in November 2022, is developing a new class of drugs designed to treat cancerous tumors that have remained elusive to other approaches.
In November 2022, FogPharma closed a $178 million Series D round led by a group of investors including Arch Venture Partners and Invus.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
03/01/2024 | Series E | $145MM | $xx.xx | $491.9MM | Alex Gorsky, Catalio Capital Management, Foresite Capital, General Catalyst, Marshall Wace, Nextech Invest, Ra Capital Management, Rock Springs Capital, Samsara Biocapital, Sixty Degree Capital, Symbiosis | |
Price per Share
$xx.xx
Shares Outstanding
23,281,563
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Alex Gorsky, Catalio Capital Management, Foresite Capital, General Catalyst, Marshall Wace, Nextech Invest, Ra Capital Management, Rock Springs Capital, Samsara Biocapital, Sixty Degree Capital, Symbiosis
|
||||||
11/21/2022 | Series D | $178MM | $xx.xx | $406.53MM | Arch Venture Partners, Casdin Capital, Cormorant Asset Management, Deerfield Management, Farallon Capital Management, Fidelity, Gv, Hbm Healthcare Investments, Invus, Milky Way Investments, Pagsgroup, T. Rowe Price, Venbio Partners | |
Price per Share
$xx.xx
Shares Outstanding
16,537,979
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.2x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Arch Venture Partners, Casdin Capital, Cormorant Asset Management, Deerfield Management, Farallon Capital Management, Fidelity, Gv, Hbm Healthcare Investments, Invus, Milky Way Investments, Pagsgroup, T. Rowe Price, Venbio Partners
|
||||||
03/01/2021 | Series C | $107MM | $xx.xx | $262.08MM | 6 Dimensions Capital, Blue Pool Capital, Cormorant Asset Management, Deerfield Management, Farallon Capital Management, Gv, Invus, Venbio Partners | |
Price per Share
$xx.xx
Shares Outstanding
7,384,710
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.4x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
6 Dimensions Capital, Blue Pool Capital, Cormorant Asset Management, Deerfield Management, Farallon Capital Management, Gv, Invus, Venbio Partners
|
||||||
05/16/2018 | Series B | $65.51MM | $xx.xx | $131.82MM | 6 Dimensions Capital, Blue Pool Capital, Boyu Capital, Deerfield Management, Gv, Horizons Ventures, Lerrink Partners, Nan Fung Group, Wuxi Apptec Corporate Ventures | |
Price per Share
$xx.xx
Shares Outstanding
4,658,112
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
6 Dimensions Capital, Blue Pool Capital, Boyu Capital, Deerfield Management, Gv, Horizons Ventures, Lerrink Partners, Nan Fung Group, Wuxi Apptec Corporate Ventures
|
||||||
05/25/2016 | Series A | $11.11MM | $xx.xx | $37.05MM | Deerfield Management | |
Price per Share
$xx.xx
Shares Outstanding
1,434,062
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Deerfield Management
|